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Graves’ disease (GD) is an autoimmune disease that
is characterized by hyperthyroidism due to circulating
autoantibodies. The most common extrathyroidal man-
ifestation is Graves’ ophthalmopathy (GO), which is
also called thyroid-related ophthalmopathy, thyroid-
associated ophthalmopathy, or Graves’ orbitopathy.
All represent inflammatory processes affecting tissues
of the orbit in patients with GD.
The inflammatory reaction mainly occurs within the
orbit: in the orbital fat, the extraocular muscles, and the
lacrimal gland. Traditionally, we use the “NOSPECS”
classification scheme (the acronym stands for: no signs
or symptoms; only signs, no symptoms; signs only;
proptosis; eye muscle involvement; corneal involve-
ment; sight visual acuity reduction) to assess GO [1–4].
Spontaneous retrobulbar pain, pain on eye movement,
eyelid erythema, conjunctival infection, chemosis,
swelling of the caruncle, and eyelid edema may also
be noted. Some patients also show complicated glau-
coma or corneal changes secondary to lagophthalmos.
The female-to-male ratio of patients with GO (rang-
ing from 2:1 to 3:1) is lower than that with GD (ranging
from 4:1 to 14:1) [1–6]. Patients show various degrees
of severity, as described above. Empirically, younger
patients seem to be protected from severe forms of
ophthalmopathy [6–8]. Genetics, smoking, and types
of treatment for GD all affect the severity of the oph-
thalmopathy [9]. In this study, we sought to identify
the reasons for the variation in severity of the clinical
manifestations, and any important factors affecting
the severity of GO.
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This study compared the ocular manifestations of Graves’ disease in different age groups and
between genders. This was a retrospective study with a chart review of 210 patients seen in the
Kaohsiung Veterans General Hospital Ophthalmology Department from 1990 to 2006. Clinical
manifestations were recorded, scored, and compared between different age groups and between
genders. A total of 77 male and 133 female patients were included. The mean age of the patients
was 48.71 years (53.80 for male and 45.77 for female patients). The average ophthalmopathy score
was 3.72 (4.51 for male and 3.26 for female patients). Age was positively correlated with ophthal-
mopathy score (p < 0.01). The male patients scored higher than the female patients, generally and
in different age groups, but the difference did not reach a statistically significant level. One hundred
and six patients underwent tests for thyroid-stimulating hormone receptor antibody (TRAb); 
92 (86.80%) were positive, but the titers did not correlate with the severity of ophthalmopathy. 
In conclusion, the severity of Graves’ ophthalmopathy is correlated with age (r=0.286). Thus, older
patients should be more closely followed up and more aggressively treated.
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We analyzed the relationship of the ophthalmo-
pathy severity score with gender, age and thyroid-
stimulating hormone (TSH) receptor antibody (TRAb)
titer to see whether any of these factors correlates with
the severity of GO.
METHODS
A retrospective chart review of 322 patients who 
visited the ophthalmology department of Kaohsiung
Veterans General Hospital with the diagnosis of GO
between January 1991 and June 2006 was performed.
After exclusion of cases with pre-existing ocular dis-
eases, such as glaucoma, cataract, and age-related mac-
ular degeneration, and cases with incomplete records,
210 patients were enrolled in this study.
All patients were diagnosed with GD and received
medical or surgical treatment for their hyperthyroid-
ism. All patients underwent routine ocular examina-
tion, including best-corrected visual acuity, color vision
testing, slit-lamp examination, intraocular pressure
(IOP) measurement, direct/indirect ophthalmoscopy,
and motility assessment. Additional autoperimetry,
visual-evoked response (VER), and orbital image stud-
ies were arranged as needed. The ocular conditions
were assessed, recorded and scored according to a
system modified from Perros et al (Table 1) [4,6]. The
condition of the lid and cornea was also assessed.
The severity of muscle involvement with diplopia
was graded as intermittent (only occasional diplopia
noted), inconstant (diplopia only present at certain
gaze positions), or constant (patient reported constant,
unavoidable diplopia). The IOP was recorded, and
the diagnosis of glaucoma was made if IOP was
> 25 mmHg in a relaxed gaze position. The diagnosis
of compressive optic neuropathy was made in pa-
tients with a drop in best-corrected visual acuity and
a decrease in color perception. All patients received
indirect ophthalmoscopy to rule out macular lesions
as causes of vision deterioration. Optic neuropathy
was confirmed by VER in patients with media opac-
ity. Neither exophthalmos nor the lid aperture was
considered in the scoring system because of a bias 
in measurement and large interindividual differences
among the normal Taiwanese population.
TRAb was detected in 106 patients and the titers
were recorded. Titers were divided into low (< 10%),
middle (≥ 10% but < 50%), and high (≥ 50%). For 
statistical analysis, we used the Mann-Whitney U test
and logistic regression.
RESULTS
In total, 133 female and 77 male patients were included.
The mean age was 48.71 ± 15.0 years (range, 3–87
years). Male patients were older (mean, 53.80 ± 14.99;
median, 56) than female patients (mean, 45.77 ± 14.26;
median, 48) (p < 0.001). Mean ophthalmopathy score
was 3.72 ± 3.58 (range, 1–15), and was higher in male
patients (mean, 4.51; median, 3.0) than in female pa-
tients (mean, 3.26; median, 2.0) (p=0.035). The severity
was correlated with age (Figure).
Because the male patients were older and showed
higher severity scores, we divided the patients into
three age groups for comparison: young, < 45 years;
middle-aged, ≥45 but <60 years; and elderly, ≥60 years
(Table 2). The male patients tended to show higher
ophthalmopathy scores in each group; however, there
was no statistically significant difference in any age
group (p = 0.613, 0.105 and 0.885 in young, middle-
aged and elderly groups, respectively, Mann-Whitney
U test). TRAb titers ranged from 1% to 90%, and did
not correlate with age or disease severity (p = 0.488
and 0.357, respectively).
Table 1. Scoring system for Graves’ ophthalmopathy
Degree of involvement Score
Lid
Lid retraction with lid lag 1
Lagophthalmos 2
Cornea
Superficial punctate lesion 1
Ulceration 2
Diplopia
Intermittent 1
Inconstant 2
Constant 3
Optic neuropathy
VA = 0.5–0.8 and color < 20/21 5
VA = 0.1–0.4 and color < 15/21 7
VA < 0.1 and color < 10/21 9
Glaucoma
Controlled with 1 line medication 1
Surgical treatment or ≥ 2 lines medication 2
VA = best-corrected visual acuity; color = color vision tested
with Ishihara color plate.
Compared to young patients, logistic regression
disclosed a statistically significant difference in scor-
ing between middle-aged (odds ratio, 3.039; p = 0.015)
and elderly patients (odds ratio, 5.404; p = 0.001), but
not among the different TRAb titer groups (Table 3).
Thus, patients with advanced age showed more severe
manifestations, but patients with higher TRAb titers
did not. We found that patients older than 45 years
showed more severe ophthalmopathy, and the severity
score correlated with age (r = 0.286).
DISCUSSION
GD affects a wide age range of people with various
clinical manifestations. Approximately 20–25% of pa-
tients with Graves’ hyperthyroidism [2] have clinically
obvious ophthalmopathy. The risk factors for oph-
thalmopathy include genetics, sex, smoking, type of
treatment for GD, advanced age, and stress. Clinical
manifestations include proptosis, periorbital edema,
sense of irritation in the eyes, excessive tearing, eye
or retro-orbital discomfort or pain, blurring of vision,
diplopia, and loss of vision. These can be noted in
patients whose status is either hyperthyroid or euthy-
roid. The severity of GO varies in different patients; it
can range from mild lid retraction without corneal
lesion to sight-threatening disease because of optic
neuropathy or exposure keratopathy.
Initial activation of T cells in GO is thought to 
be mediated by thyrotropin receptor antigen [10–12].
TRAb, not just T cells, may play an important role 
in the eye disease by activating the TSH receptors of
fibroblasts and adipocytes [13]. This immunoglobu-
lin was called long-acting thyroid stimulator (LATS)
after being discovered in 1956 by Adams and Purves
[14], and was considered to be a specific marker for
GD. Therefore, it can be used for the confirmation of
GD and ophthalmic GD, even in patients with euthy-
roid status. Moreover, monitoring LATS levels may
be useful when testing the effects of therapy on GD
because the titers of the antibodies may fluctuate at
different stages of the disease.
We sought a pattern of correlation between the clin-
ical severity and TRAb titers; however, the titers in this
study ranged widely (1–90%; mean, 36.3%). The TRAb
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Table 2. Average ophthalmopathy score in each age
group
Age (yr) Median score p
< 45 (n = 82) 0.613
Male (n = 24) 2.00
Female (n = 58) 2.00
≥ 45 and < 60 (n = 84) 0.105
Male (n = 27) 3.00
Female (n = 57) 2.00
≥ 60 (n = 44) 0.885
Male (n = 26) 4.00
Female (n = 18) 3.50
Table 3. Results of logistic regression
Coefficient SE OR p
Gender (M/F) 0.591 0.366 1.806 0.106
Age (middle/young) 1.112 0.456 3.039 0.015*
Age (old/young) 1.687 0.504 5.404 0.001*
TRAb (median/low)† −0.188 0.892 0.829 0.833
TRAb (high/low)† 1.313 0.938 3.718 0.162
TRAb (unknown/low)‡ 0.249 0.849 1.283 0.769
*p < 0.05 is considered statistically significant; †TRAb < 10% is considered low and > 55% is considered high; ‡unknown represents
patients not tested. SE = standard error; OR = odds ratio; TRAb = thyroid-stimulating hormone receptor antibody.
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Figure. Correlation of age and ophthalmopathy score (r = 0.286,
p < 0.001).
titer fluctuates with disease activity and stage of treat-
ment, and patients may yield different readings as
the disease progresses or enters remission. We found
no significant correlation between TRAb titers and
the ophthalmopathy severity score (p = 0.357), nor did
TRAb titers correlate with age (p = 0.488) or gender.
Sequential assessment of TRAb titers might be nec-
essary before further conclusions can be reached. As
with any retrospective study, our data were limited
to chart records. TRAb titers were not assessed in
every patient, and not every patient was tested accord-
ing to disease severity sequentially. Further study of
more patients or assessment of other antibodies are
needed before it can be concluded that TRAb titers
have no significant relationship with GO severity.
We analyzed the relationships among ophthalmo-
pathy severity score and age, sex, and TRAb titers and
found that severity correlated well with age (p = 0.000,
r = 0.286). Older patients had more severe ophthal-
mopathy, especially those over 45 years old.
There are some other factors that worsen the man-
ifestations of GO. Smoking is a well-known risk fac-
tor for GO, with odds ratios from 4.4 to 7.7 reported
[15,16]. Smoking also increases the risk for GD (odds
ratio 3.3 comparing current smokers with those who
have never smoked) [16], and has been noted to have
a deleterious effect on remission of GD, especially in
male patients [17]. Cigarette smoking also influences
the effect of treatment for GD/GO; it is an independ-
ent risk factor for relapse of GD after antithyroid drug
treatment. Smoking attenuates the effect of orbital
radiotherapy and high-dose systemic glucocorticoids
in GO patients and causes a higher rate of progres-
sion of eye disease after radioiodine therapy [18]. In
Taiwan, cigarette smoking is less common among
women than in the West, but there is a significantly
higher prevalence of smoking in women with GO and
nontoxic nodular goiter than among normal, healthy
control individuals [19]. This might also contribute to
the observed asymmetry of severity between male and
female patients. Smoking cessation has been advised
to decrease morbidity from GD. However, this rec-
ommendation has not succeeded in reducing smok-
ing in Western countries [16,20]. In this study, the effect
of smoking was not included in the analysis because
of the limitations of retrospective chart review.
Besides smoking, the status of thyroid function
has also been discussed. Patients with GO may have
a hyper-, hypo-, or euthyroid status, but neither
subtotal thyroidectomy nor antithyroid medications
show beneficial or harmful effects with respect to eye
changes [21].
There were some limitations of this study. The
patients were gathered from the outpatient department
of a single medical center, which may have caused 
a selection effect. A community-based survey is sug-
gested to validate our findings. Female patients out-
numbered male patients in this study, but showed
lower average severity. This may be explained by dif-
ferences in help-seeking behavior between genders.
Thus, young female patients may have been less tol-
erant of changes in their appearance or the discom-
fort caused by GO; thus, they may have tended to seek
medical help for more minor conditions, resulting in
a lower severity score.
Male patients are known to suffer from more severe
GO than female patients [6]. In this study, we also
noted this trend. However, the male patients were
also older than the female patients. To evaluate the
significance of age and gender, we performed differ-
ent groupings for analysis. We noted that the odds
ratio was 3.039 from a comparison of the middle and
young age groups and 5.404 from a comparison of
the old and young age groups (logistic regression,
Table 3). This analysis suggests that age is a signifi-
cant factor influencing the severity of GO. In conclu-
sion, we suggest that older patients with GD should
have their ophthalmopathy monitored more closely;
once ocular symptoms develop, close follow-up as
well as aggressive treatment might be needed.
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